2024-09-24 - Analysis Report
## AbbVie Inc (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc is a global pharmaceutical company that develops, manufactures, and markets a wide range of drugs, including Humira, a blockbuster treatment for autoimmune diseases. 

**Performance Summary:**

* **Return:** ABBV has generated a cumulative return of 152.64% over the period, outperforming the S&P 500 (VOO) by 19.54%. This represents a 60.77% relative outperformance against the index based on historical data.
* **Price Momentum:** The recent price trend shows a slight downward bias.  
    * 5-day moving average: 193.27
    * 20-day moving average: 195.09
    * 60-day moving average: 185.77
* **Technical Indicators:**
    * **RSI (41.39):**  The RSI is below 50, suggesting that the stock is in oversold territory. 
    * **PPO (-0.42):** The PPO is negative, indicating a weak price momentum.
    * **Relative Divergence:** The recent 20-day relative divergence is -8.0, indicating a short-term downward trend.
    * **Expected Return (24.53%):**  Based on current market conditions and historical data, there is a potential for a 24.53% return over the next 5 years.
* **Earnings Analysis:** ABBV has consistently exceeded earnings expectations in recent quarters. 
    * **Latest Quarter (2024-07-25):** EPS was 2.65, exceeding the expected EPS of 2.57.

**Overall Analysis:**

ABBV has shown strong performance in the past, outperforming the S&P 500. Currently, the stock is showing signs of weakness in the short-term, evidenced by the declining price momentum and negative technical indicators. However, the strong earnings performance and the potential for future growth may indicate opportunities for long-term investors. 

**Disclaimer:** This analysis is for informational purposes only and should not be considered financial advice. It's essential to conduct thorough research and consult with a financial professional before making any investment decisions.